The 4th Oncolytic Virotherapy Summit is dedicated to improving the commercial success of oncolytic viruses, in stand-alone and combination therapies.

As many oncolytic viruses progress through the clinical pipelines, drug developers need to ensure that their therapies are safe, efficacious and commercially viable. Make sure you stay ahead of the game and join Oncolytic Virotherapy Summit, where you will have an opportunity to pick the brains of 100+ senior industry peers and tackle your challenges in discovery, clinical development, manufacturing and regulations of oncolytic virotherapy.

This year we will be incorporating commercial insights from companies such as Merck, Virogen, Sagetis, Lokon Pharma, Replimmune, Western Oncolytics, DNAtrix and many more, which will allow you to learn from their case studies and improve your development strategies. Participate in the interactive roundtable and workshops to build strategies that maximise success in the clinic and commercially.

Sounds interesting? Find out more – get free event brochure here: http://bit.ly/2KzCLIh